Generalised myasthenia gravis (gMG) is a chronic autoimmune disease of the neuromuscular junction characterized by fluctuating muscle weakness. The disease is primarily driven by pathogenic autoantibodies targeting components of the postsynaptic membrane, most commonly the acetylcholine receptor (AChR), leading to impaired neuromuscular transmission.
B cells play a central role in the pathogenesis of gMG through autoantibody production, antigen presentation, and modulation of immune responses. CD19-positive B cells, expressed across most stages of B-cell development, represent a broad population including naïve and memory B cells as well as plasmablasts.
Targeting CD19-positive B cells has therefore emerged as a promising therapeutic approach in gMG.
Braintop site: R.E. Amgen n.v./s.a., Telecomlaan 5-7, 1831 Diegem – BEL-335-26-80008 – v1.0 - Creation date: 9 March 2026
Dermatology
Accrédité pour médecins (N° 25034524 - 1 point)
Rhumatology & Orthopedy
Accrédité pour médecins (N° - point)
Healthcare
Accrédité pour 'autres' (N° 26000450001 - 1 point)
Healthcare
Accrédité pour 'autres' (N° 25031523 - 1 point)
Accrédité pour les médecins - 25034524 - 1CP
